Research programme : antibody drug conjugate therapeutics - Bristol Myers Squibb
Latest Information Update: 16 Jun 2023
At a glance
- Originator Bristol-Myers Squibb
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 24 Apr 2023 Tubulis has patents for TubTag technology, prior to April 2023 (Tubulis pipeline, April 2023)
- 20 Apr 2023 Bristol Myers Squibb and Tubulis enters into a licensing agreement to develop antibody drug conjugates in USA
- 20 Apr 2023 Early research in Solid tumours in USA (Parenteral), prior to April 2023